京都大学大学院医学研究科 血液・腫瘍内科学

研究

ホーム ＞ 研究 ＞ 臨床研究グループ

臨床研究グループ

2023年の業績

  • Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, Ara T, Kuriyama T, Katayama Y, Kawakita T, Kanda Y, Onizuka M, Ichinohe T, Atsuta Y, Terakura S. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 3(1):67, 2023.
  • Inoue Y, Morishima S, Kato K, Ito A, Nakano N, Kuriyama T, Kawakita T, Mori Y, Suehiro Y, Itonaga H, Miyazaki Y, Imada K, Tomori S, Kanda J, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma.Bone Marrow Transplant, 2023.
  • Yamasaki S, Mizuno S, Iwasaki M, Seo S, Uchida N, Shigesaburo M, Nakano N, Ishiwata K, Uehara Y, Eto T, Takase K, Kawakita T, Tanaka M, Sawa M, Katayama Y, Nawa Y, Makoto O, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics. Ann Hematol, 102(6): 1549-1559. 2023.
  • Shimazu Y, Mizumoto C, Chonabayashi K, Hanyu Y, Kanda J, Takaori-Kondo A. Successful treatment with cyclosporine of pure red cell aplasia induced by obinutuzumab bendamustine therapy.Ann Hematol, 2023.
  • Iemura T, Kondo T, Ueda A, Maeda T, Kitawaki T, Arai Y, Kanda J, Ikeda T, Imada K, Ishikawa T, Anzai N, Itoh M, TakeOka T, Akasaka T, Yago K, Yonezawa A, Arima N, Kitano T, Nohgawa M, Watanabe M, Moriguchi T, Yamashita K, Ueda Y, Matsumoto K, Takaori-Kondo A. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Ann Hematol. 2023.
  • Shimazu Y, Kanda J, Kosugi S, Ito T, Kaneko H, Imada K, Shimura Y, Fuchida SI, Fukushima K, Tanaka H, Yoshihara S, Ohta K, Uoshima N, Yagi H, Shibayama H, Yamamura R, Tanaka Y, Uchiyama H, Onda Y, Adachi Y, Hanamoto H, Takahashi R, Matsuda M, Miyoshi T, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.Sci Rep . 13(1): 5159, 2023.
  • Itonaga H, Miyazaki Y, Aoki K, Shingai N, Ozawa Y, Fukuda T, Kataoka K, Kawakita T, Ueda Y, Ara T, Tanaka M, Katayama Y, Sawa M, Eto T, Kanda J, Atsuta Y, Ishiyama K. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. Ann Hematol, 102(5):1215-1227, 2023.
  • Toratani K, Watanabe M, Kanda J, Oka T, Hyuga M, Arai Y, Iwasaki M, Sakurada M, Nannya Y, Ogawa S, Yamada T, Takaori-Kondo A. Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.Int J Hematol . 2023.
  • Morita-Fujita M, Shindo T, Iemura T, Arai Y, Kanda J, Okada K, Ueda Y, Yoshiyuki O, Anzai N, Mori T, Ishikawa T, Otsuka Y, Yonezawa A, Yuhi N, Imada K, Oba A, Itoh M, Okamoto Y, Kitano T, Ikeda T, Kotani S, Akasaka T, Yago K, Watanabe M, Nohgawa M, Tsuji M, TakeOka T, Yamamoto R, Arima N, Yoshinaga N, Hishizawa M, Yamashita K, Kondo T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group. Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy.Transplant Cell Ther, 29(6): 347.e1-347.e11, 2023.
  • Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, Hirayama M, Ara T, Nakamae H, Ota S, Maruyama Y, Eto T, Uchida N, Tanaka M, Ishiwata K, Koi S, Takahashi S, Ozawa Y, Onizuka M, Kanda Y, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. Transplant Cell Ther, 29(6): 365.e1-365.e11, 2023.
  • Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, Eto T, Takada S, Kako S, Uchida N, Kawakita T, Yoshiko H, Ichinohe T, Atsuta Y, Terakura S; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.Int J Hematol , 117(6): 889-899, 2023.
  • Sun H, Wada F, Kanda J, Mizumoto C, Ito T, Masano Y, Uchida Y, Hatano E, Yurugi K, Hishida R, Yamashita K, Takaori-Kondo A. An adult case of refractory autoimmune neutropenia after liver transplantation. Int J Hematol. 2023.
  • Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Ishitsuka K, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M, Kato K. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study.Bone Marrow Transplant, 58(4):462-464, 2023.
  • Kataoka A, Mizumoto C, Kanda J, Iwasaki M, Sakurada M, Oka T, Fujimoto M, Yamamoto Y, Yamashita K, Nannya Y, Ogawa S, Takaori-Kondo A. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. Int J Hematol, 117(6):919-924, 2023.
  • Konuma T, Itonaga H, Ishiyama K, Hamamura A, Uchida N, Ozawa Y, Katayama Y, Sakurai M, Ueda Y, Matsuoka KI, Kawakita T, Eto T, Ara T, Kanda J, Onizuka M, Fukuda T, Atsuta Y. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real-world registry study in Japan. Am J Hematol. 98(4): E68-E71, 2023.
  • Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 114(4): 1297-1308, 2023.
  • Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. Int J Hematol. 117(3): 409-420, 2023.
  • Shimomura Y, Komukai S, Kitamura T, Sobue T, Kurosawa S, Doki N, Katayama Y, Ozawa Y, Matsuoka KI, Tanaka T, Kako S, Sawa M, Kanda Y, Nakamae H, Nakazawa H, Ueda Y, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis. Bone Marrow Transplant. 58(2): 186-194, 2023.
  • Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, Takaori-Kondo A. Significance of Omitting Day 11 Mini-Dose Methotrexate for GVHD Prophylaxis After Unrelated Bone Marrow Transplantation. Transplant Cell Ther. 29(2): 119.e1-119.e7, 2023.
  • Matsuda K, Konuma T, Fuse K, Masuko M, Kawamura K, Hirayama M, Uchida N, Ikegame K, Wake A, Eto T, Doki N, Miyakoshi S, Tanaka M, Takahashi S, Onizuka M, Kato K, Kimura T, Ichinohe T, Takayama N, Kobayashi H, Nakamae H, Atsuta Y, Kanda J, Yanada M. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study. Br J Haematol. 201(1): 106-113, 2023.
  • Konuma T, Kanda J, Uchida N, Nishijima A, Tanaka M, Ozawa Y, Sawa M, Onizuka M, Ota S, Maruyama Y, Kanda Y, Kawakita T, Ara T, Eto T, Nakamae H, Kimura T, Fukuda T, Atsuta Y; Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation. Hematol Oncol. 41(1): 147-158, 2023.
  • Nakamura N, Arai Y, Kitawaki T, Jo T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Takaori-Kondo A. Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy. Br J Haematol. 200(1): e1-e3, 2023.
  • Hamada R, Sato S, Miyasaka J, Murao M, Matsushita M, Kajimoto T, Otagaki A, Asano T, Nankaku M, Kondo T, Arai Y, Kanda J, Takaori-Kondo A, Ikeguchi R, Matsuda S. Belt Electrode-Skeletal Muscle Electrical Stimulation During Early Hematopoietic Post-Transplantation To Prevent Skeletal Muscle Atrophy and Weakness. Transplant Cell Ther. 29(1): 51.e1-51.e7, 2023.
  • Jo T, Arai Y, Hatanaka K, Ishii H, Ono A, Matsuyama N, Mori J, Koh Y, Azuma F, Kimura T. Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation. Cytotherapy. 25(4): 407-414, 2023.
  • Shibata S, Arai Y, Kondo T, Mizuno S, Harada K, Miyakoshi S, Uchida N, Maruyama Y, Eto T, Katsuoka Y, Matsue K, Nishiwaki K, Takada S, Doki N, Itoh M, Nagafuji K, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Yanada M. Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplant Cell Ther. 29(5): 332.e1-332.e11, 2023.
  • Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. Blood Adv. 7(12): 2699-2708, 2023.
  • Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023.
  • Jo T, Arai Y Oshima S, Kondo T, Harada K, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Kuriyama T, Ikegame K, Katayama Y, Ota S, Ara T, Kawakita T, Onizuka M, Ichinohe T, Atsuta Y, Yanada M. Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic AML: a quantitative approach. Br J Haematol. 2023.